Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Annovis Bio, Inc. Common Stock (NY:ANVS)

1.110 +0.030 (+2.78%)
Delayed Quote Updated: 1:06 PM EST, Nov 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Annovis Bio, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Annovis Bio, Inc. Receives Continued Listing Standard Notice from the NYSE
From Annovis Bio Inc.
Via GlobeNewswire
MissionIRNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) CEO to Present at Two November Biotechnology Industry Conferences
Via Investor Brand Network
News headline image
Annovis to Participate in U.S. Biotech Day 2026 and Pharma Partnering Summit 2026
Maria Maccecchini, PhD, CEO of Annovis, will join industry panel with pharma leaders and present company updates 
From Annovis Bio Inc.
Via GlobeNewswire
NetworkNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) to Present Buntanetap Research and Phase 3 Trial Updates at Alzheimer Conference
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Annovis to Attend the CTAD 2026 with Three Presentations
From Annovis Bio Inc.
Via GlobeNewswire
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Collaborates With Weave Bio to Support Buntanetap NDA Preparation
Via Investor Brand Network
Topics Artificial Intelligence
News headline image
Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer’s Disease
From Annovis Bio Inc.
Via GlobeNewswire
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) to Host Corporate Update Webinar on Clinical Programs and Milestones
Via Investor Brand Network
News headline image
Annovis to Host Corporate Update Webinar on September 2, 2026
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
Annovis Provides Corporate Updates and Second Quarter 2026 Financial Results
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease
From Annovis Bio Inc.
Via GlobeNewswire
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Promotes Cheng Fang to Chief Scientific Officer
Via Investor Brand Network
News headline image
Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer
From Annovis Bio Inc.
Via GlobeNewswire
MissionIRNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Regains NYSE Listing Compliance
Via Investor Brand Network
News headline image
Annovis Bio Regains NYSE Listing Compliance
From Annovis Bio Inc.
Via GlobeNewswire
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Prices $15 Million Public Offering of Common Stock and Warrants
Via Investor Brand Network
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Announces Proposed Public Offering of Common Stock and Warrants
Via Investor Brand Network
News headline image
Annovis Announces Pricing of $15.0 Million Public Offering of Common Stock and Accompanying Warrants
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants
From Annovis Bio Inc.
Via GlobeNewswire
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Reports First-Quarter Progress Across Phase 3 Alzheimer’s and Parkinson’s Programs
Via Investor Brand Network
News headline image
Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results
From Annovis Bio Inc.
Via GlobeNewswire
MissionIRNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) CEO to Present Alzheimer’s Multi-Protein Research at Fierce Biotech Week 2026
Via Investor Brand Network
News headline image
Annovis CEO to Present on Multi-Protein Model of Alzheimer's Disease at Fierce Biotech Week 2026
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
Annovis Publishes Phase 2/3 Alzheimer's Trial Results in Nature Portfolio
From Annovis Bio Inc.
Via GlobeNewswire
BioMedNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Closes $10 Million Offering To Fund Phase 3 Milestones Through 2027
Via Investor Brand Network
News headline image
Annovis Closes $10 Million Offering, Extending Cash Runway Through Phase 3 Alzheimer's Disease 6-Month NDA Submission
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants
From Annovis Bio Inc.
Via GlobeNewswire
News headline image
Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections
From Annovis Bio Inc.
Via GlobeNewswire
InvestorNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Highlights Buntanetap Development in The Scientist Publication
Via Investor Brand Network
News headline image
Annovis Publishes Historical Review of Buntanetap in The Scientist
From Annovis Bio Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.